Locally Advanced Bladder Cancer
Locally advanced cancer refers to when the cancer cells have spread from where they started to nearby tissues or to lymph nodes. With bladder cancer, this means that the cancer has spread to the walls of the bladder or to the lymph node, but it has not spread to any other parts of the body.
Metastatic Bladder Cancer
Bladder cancer is referred to as “metastatic” when it spreads outside of the bladder to other parts of the body.
These are some things to consider when discussing your treatment plan for advanced bladder cancer with your healthcare provider. Sharing this information can help you and your healthcare team decide what your next treatment option could be.
Together with your healthcare provider, take control of your treatment plan with TRODELVY.
TRODELVY is designed to carry anticancer medicine to cells that have the Trop-2 protein, which is more often present on certain types of cancer cells in comparison to normal cells, including those found in advanced bladder cancer. See how TRODELVY is designed to work.
TRODELVY® (sacituzumab govitecan-hziy) is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract that have spread or cannot be removed by surgery. TRODELVY may be used if you have received a platinum-containing chemotherapy medicine and also received an immunotherapy medicine.*
It is not known if TRODELVY is safe and effective in people with moderate or severe liver problems. It is not known if TRODELVY is safe and effective in children.
Here are some additional resources that may be helpful to patients, families, and care partners dealing with advanced bladder cancer. The following resources are not controlled or owned by Gilead, and Gilead is not responsible for their content.
American Cancer Society: Find local cancer support.
Bladder Cancer Advocacy Network (BCAN): Connect with a community of patients, care partners, survivors, advocates, and medical and research professionals dedicated to helping people with bladder cancer.
Bladder Cancer Matters Podcast: Listen to a podcast created for the bladder cancer community that discusses bladder cancer research, treatment, caregiving, and more.
Cancer Support Community: The largest professionally led nonprofit network of cancer support worldwide, providing access to information, support, and other resources.
Inspire Online Community: Ask questions and connect with other people with bladder cancer and care partners.
TRODELVY® (sacituzumab govitecan-hziy) is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract that have spread (metastatic) or cannot be removed by surgery, and who have received a platinum-containing chemotherapy medicine and also received an immunotherapy medicine.
This indication is approved based on medical studies that measured how many patients responded and how long they responded. Continued approval may depend on benefit demonstrated in additional medical studies.
It is not known if TRODELVY is safe and effective in people with moderate or severe liver problems or in children.
Do not receive TRODELVY if you have had a severe allergic reaction to TRODELVY. Ask your healthcare provider if you are not sure.
Allergic and infusion-related reactions which can be serious and life-threatening. Tell your healthcare provider or nurse right away if you get any of the following symptoms during your infusion of TRODELVY or within 24 hours after: swelling of your face, lips, tongue, or throat; hives; skin rash, itching, or flushing of your skin; fever; difficulty breathing or wheezing; lightheadedness, dizziness, feeling faint, or pass out; or chills or shaking chills (rigors).
Nausea and vomiting are common with TRODELVY and can sometimes be severe. Before each dose of TRODELVY, you will receive medicines to help prevent nausea and vomiting along with medicines to take home with instructions about how to take them. Call your healthcare provider right away if you have nausea or vomiting that is not controlled with the medicines prescribed for you. Your healthcare provider may decide to decrease your dose or stop TRODELVY if your nausea and vomiting is severe and cannot be controlled with anti-nausea medicines.
Before receiving TRODELVY, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain medicines may affect the way TRODELVY works.
The most common side effects of TRODELVY include decreased white blood cell (leukocyte and lymphocyte) and red blood cell counts, feeling tired or weak, hair loss, constipation, increased sugar levels in the blood, decreased protein levels (albumin) in the blood, decreased appetite, changes in kidney function test, increased levels of enzyme called alkaline phosphatase in the blood (test for liver or bone problems), and decreased levels of magnesium, potassium, and sodium in the blood.
These are not all of the possible side effects of TRODELVY. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Please click to see Important Facts about TRODELVY, including Important Warning.